Department of Urology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China.
Pharm Biol. 2023 Dec;61(1):674-682. doi: 10.1080/13880209.2023.2199786.
Zhibai Dihuang pill (ZD), a traditional Chinese medicine nourishes Yin and reduces internal heat, is believed to have therapeutic effects on urinary tract infections (UTIs).
To explore the effects and mechanism of modified ZD (MZD) on UTI induced by extended-spectrum β-lactamase (ESBLs) .
Thirty Sprague-Dawley rats were randomly divided into control, model (0.5 mL 1.5 × 10 CFU/mL ESBLs ), MZD (20 g/kg MZD), LVFX (0.025 g/kg LVFX), and MZD + LVFX groups (20 g/kg MZD + 0.025 g/kg LVFX), = 6. After 14 days of treatment, serum biochemical indicators, renal function indicators, bladder and renal histopathology, and urine bacterial counts in rats were determined. Additionally, the effects of MZD on ESBLs biofilm formation and related gene expression were analyzed.
MZD significantly decreased the count of white blood cells (from 13.12 to 9.13), the proportion of neutrophils (from 43.53 to 23.18), C-reactive protein (from 13.21 to 9.71), serum creatinine (from 35.78 to 30.15), and urea nitrogen (from 12.56 to 10.15), relieved the inflammation and fibrosis of bladder and kidney tissues, and reduced the number of bacteria in urine (from 2174 to 559). In addition, MZD inhibited the formation of ESBLs biofilms (2.04-fold) and decreased the gene expressions of , and (1.41-1.62-fold).
MZD treated ESBLs induced UTI inhibited biofilm formation, providing a theoretical basis for the clinical application of MZD. Further study on the clinical effect of MZD may provide a novel therapy option for UTI.
知柏地黄丸是一种传统的中药,具有滋阴降火的功效,被认为对尿路感染(UTIs)有治疗作用。
探讨改良知柏地黄丸(MZD)对产超广谱β-内酰胺酶(ESBLs)的尿路感染的作用及机制。
30 只 Sprague-Dawley 大鼠随机分为对照组、模型组(0.5ml 1.5×10 CFU/ml ESBLs)、MZD 组(20g/kg MZD)、左氧氟沙星(LVFX)组(0.025g/kg LVFX)和 MZD+LVFX 组(20g/kg MZD+0.025g/kg LVFX),每组 6 只。治疗 14 天后,检测大鼠血清生化指标、肾功能指标、膀胱和肾脏组织病理学及尿液细菌计数,并分析 MZD 对 ESBLs 生物膜形成及相关基因表达的影响。
MZD 可显著降低白细胞计数(从 13.12 降至 9.13)、中性粒细胞比例(从 43.53 降至 23.18)、C 反应蛋白(从 13.21 降至 9.71)、血清肌酐(从 35.78 降至 30.15)和尿素氮(从 12.56 降至 10.15),缓解膀胱和肾脏组织的炎症和纤维化,减少尿液中细菌数量(从 2174 降至 559)。此外,MZD 抑制 ESBLs 生物膜的形成(降低 2.04 倍),并降低 、 、 (分别降低 1.41-1.62 倍)的基因表达。
MZD 治疗 ESBLs 诱导的 UTI 抑制了生物膜的形成,为 MZD 的临床应用提供了理论依据。进一步研究 MZD 的临床疗效可能为 UTI 提供一种新的治疗选择。